Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 7/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.43 |
| ▸ | SCN2B | O60939 | 1/20 | 0.43 |
| ▸ | SCN1A | P35498 | 1/20 | 0.43 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.43 |
| ▸ | F11 | P03951 | 5/20 | 0.40 |
| ▸ | F7 | P08709 | 5/20 | 0.40 |
| ▸ | KLRK1 | P26718 | 1/20 | 0.40 |
| ▸ | MICA | Q29983 | 1/20 | 0.40 |
| ▸ | RAET1L | Q5VY80 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 4/20 | 0.39 |
| ▸ | GUSB | P08236 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11940891 | 0.90 | SCN9A (0.42) | SCN9ASCN5ASCN2BSCN1ASCN1B | |
| SCHEMBL11027843 | 0.86 | F11 (0.42) | SCN9AF11F7HDAC8F10 | |
| SCHEMBL11026001 | 0.85 | F11 (0.47) | F11F7F10GUSBCCR2 | |
| SCHEMBL12687224 | 0.85 | F10 (0.39) | F11F7HDAC8F10GUSB | |
| SCHEMBL11023614 | 0.85 | F7 (0.45) | F11F7F10 | |
| SCHEMBL11028638 | 0.84 | F11 (0.47) | F11F7F10GUSB | |
| SCHEMBL11028289 | 0.84 | SCN2B (0.43) | SCN9ASCN5ASCN2BSCN1ASCN1B | |
| SCHEMBL11024124 | 0.84 | F11 (0.43) | SCN9AF11F7PTPN1F10 | |
| SCHEMBL11026899 | 0.83 | F11 (0.45) | SCN9AF11F7F10 | |
| SCHEMBL12466206 | 0.83 | F11 (0.40) | SCN9ASCN5AF11F7F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809369-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | claimed |
| EP-2668165-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-04 | — | — | EP | claimed |
| WO-2012101068-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-02 | — | — | WO | claimed |
| US-20120190677-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | US | claimed |
| US-8809369-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809369-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809369-B2 | Tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2668165-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-04 | — | — | EP | disclosed |
| WO-2012101068-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| US-20120190677-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | US | disclosed |
| US-20120190677-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | US | disclosed |
| US-20120190677-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190677-A1 | NOVEL TETRAHYDROQUINOLINE DERIVATIVES | RAB1A, RABL3, RAB7A | SCN9A 1420/4885SCN5A 971/4885SCN2B 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.